Back to Search
Start Over
SARS-CoV-2 Messenger RNA Vaccine Immunogenicity in Solid Organ Transplant Recipients With Prior COVID-19.
- Source :
-
Transplantation [Transplantation] 2021 Nov 01; Vol. 105 (11), pp. e270-e271. - Publication Year :
- 2021
-
Abstract
- Competing Interests: D.L.S. has received consulting or speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific. R.K.A. has study/grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. The other authors declare no conflicts of interest.
- Subjects :
- Aged
Antibodies, Viral immunology
COVID-19 blood
COVID-19 diagnosis
COVID-19 immunology
COVID-19 Vaccines administration & dosage
Convalescence
Female
Humans
Male
Middle Aged
Organ Transplantation adverse effects
Prospective Studies
SARS-CoV-2 immunology
SARS-CoV-2 isolation & purification
Vaccines, Synthetic administration & dosage
Vaccines, Synthetic immunology
mRNA Vaccines
Antibodies, Viral blood
COVID-19 prevention & control
COVID-19 Vaccines immunology
Immunogenicity, Vaccine
Transplant Recipients statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1534-6080
- Volume :
- 105
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Transplantation
- Publication Type :
- Report
- Accession number :
- 34284420
- Full Text :
- https://doi.org/10.1097/TP.0000000000003900